On May 9, 2001. The Food and Drug Administration (FDA) issued a Public Health Advisory to announce significant safety-related updates to the labeling of Sporanox products and Lamisil tablets. Sporanox and Lamisil are used to treat nail (onychomycosis), skin and other systemic fungal infections. The FDA believes there is real risk of developing congestive heart failure (CHF) associated with the use of Sporanox. Both Sporanox and Lamisil have been associated with serious liver problems resulting in liver failure, transplantation and even death.
Results of recent studies of Sporanox showed that the drug can weaken the force of the heart muscle's contractions. This condition, sometimes called "negative inotropic effect" was observed when Sporanox was injected intravenously into anesthetized dogs and healthy human volunteers. In these studies, the adverse effect on the heart muscle resolved once the drug was stopped.
--Disturbances of the gut such as indigestion, diarrhoea, constipation, nausea, vomiting or abdominal pain
--Skin reactions such as rash or itching
--Alteration in results of liver function tests
--Inflammation of the liver (hepatitis)
--Disorder of the peripheral nerves causing weakness and numbness (peripheral neuropathy)
--Low blood potassium level (hypokalaemia)
--Hair loss (alopecia)
If you or a loved one has used the prescription drug Sporanox and noticed adverse side effects, such as those listed above, you should contact a physician immediately. If you wish to discuss your legal rights, are interested in more information on Sporanox litigation, or if you have information about a case that you would like to share with us, please contact the law offices of Keller & Keller LLP for a free consultation concerning your potential rights. Keller & Keller LLP has office locations in Indiana, Michigan and New Mexico and will be able to evaluate your potential case at no cost to you.